|
|
Overview
Highlights
News
Chart
Contacts
|
|
|
|
|
|
|
|
|
| | "Announced
a 63% increase
in sales revenues for the current quarter compared to last year's first
quarter"
|
| |
|
| |
|
|
|
| Approximate
Financial Snapshot as of 3/19/07 |
|
| Shares
Outstanding |
11.34M |
| 52
Wk Hi/Lo |
19.59/
5.50
|
| Market
Cap |
$207.6M |
| Recent
Price |
$18.30 |
|
|
|
|
|
|
3/19/07
Rochester
Medical (ROCM)
Website:
www.rocm.com
A
study at the Johns Hopkins Burn Center showed infection rates fell 70% when
doctors switched from using uncoated latex catheters to Rochester's device.
Overview
Rochester Medical (ROCM) develops,
manufactures, and markets innovative urinary continence and urine drainage care
products for the extended care and acute care markets in the United States
and internationally. Its extended care products include a line of male
external catheters for managing male urinary incontinence and a line of
intermittent catheters for managing both male and female urinary retention.
The company's extended care products also comprise the FemSoft
Insert, a liquid-filled and conformable urethral insert for managing female
stress urinary incontinence in adult females; and Personal Catheters, a line
of disposable intermittent catheters manufactured from silicone in three
lengths with multiple diameters for male, female, and pediatric use. Its
acute care products comprise a line of Foley catheters, including Release-NF
catheter, an antibacterial Foley catheter that reduces the incidence of
hospital acquired urinary tract infection.
RMC offers silicone Foley
catheters in a two-lumen version for urinary drainage management and in a
three-lumen version that also supports irrigation of the urinary tract. It
also provides antibacterial and hydrophilic intermittent catheters. In
addition, the company manufactures and sells male external catheters made
from proprietary non-latex and non-silicone material to certain private
label customers. It sells its products under the Rochester Medical brand
name through direct sales force, primarily for distributors, extended care
facilities, individual hospitals, and healthcare institutions in the United
States; and through independent distributors internationally.
This is an abbreviated profile
and we encourage readers interested in learning more about Rochester Medical
to visit
the company website at www.rocm.com.
ROCM
Investor Highlights
- Reported record sales of
$7,512,000 for the quarter ending 12/31/06 compared to $4,607,000 for
the first quarter of last year. It also reported net income of
$31,467,000 or $2.59 per diluted share compared to a net income of
$311,000 or $.03 per diluted share for the first quarter of last year.
- Quarterly results include $38,605,000 of
income resulting from the previously announced lawsuit settlements.
- The 63% increase in sales
revenues for the current quarter compared to last year's first quarter
resulted from increased Rochester Medical Brand sales, primarily
attributable to increased international sales of Rochester Medical Brand
products resulting from the previously announced acquisition in the
United Kingdom, and also from increased Private Label sales.
- "This has certainly been an eventful
quarter," said Company CEO and President Anthony J. Conway.
"We were awarded a National Group Purchasing Contract by Premier
Purchasing Partners, L.P.; we renewed our Private Label sales agreement
with Hollister, Inc.; we secured two lawsuit settlements in our
anti-trust litigation; and we realized strong sales and earnings. We are
pleased with the Company's progress, and we look forward to a good
year."
- Announced that it has signed a new Private
Label Agreement for supply of Male External Catheters (MECs) to
Hollister Incorporated and also announced that the parties have amended
their 2003 OEM/Private Label Agreement.The MEC Agreement has a five year
term commencing on January 1, 2007. Under the Agreement Rochester
Medical will continue to supply Hollister with its requirements of
non-latex Male External Catheters for sale under the Hollister brand
worldwide, excluding the United Kingdom.
- Announced that group purchasing
organization, Premier Purchasing Partners, L.P. ("Premier")
has awarded the Company a national contract for supplying Premier's
participating members with urological products, including Rochester
Medical's line of infection control catheters. Premier is one of the
largest Group Purchasing Organizations in the United States with over
$27 billion in contract purchases per year. Its members include more
than 1,500 hospital facilities and hundreds of other care sites. The
contract has a 27 month term from the effective date of March 1, 2007.
Initial marketing efforts are expected to commence prior to that
date.
Recent
News and Press Releases
Battle
Scarred
Rochester
Medical Reports Record First Quarter
Rochester
Medical Corporation Announces Settlement Agreement With C.R. Bard, Inc.
Rochester
Medical Announces Agreements With Hollister Incorporated
Rochester
Medical Corporation Announces Settlement Agreement With Premier
Rochester
Medical Corporation Awarded National Group Purchasing Contract for
Urological Products
For the latest Quote
and News on ROCM Click
Here.
Three
Month Chart
Outlook
Rochester Medical
Corporation, a small-cap growth company in the health care sector, is
expected to significantly outperform the market over the next six months
with average risk. Source
MSN
Contacts
Rochester Medical Corp.
One Rochester Medical Drive
Stewartville, MN 55976
Phone: 507-533-9600
Fax: 507-533-4232
SEC Filings
ROCM filings with the SEC can be found here.
All Fillings are current and the Company is fully reporting.
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of ROCM, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site. SmallCapReview.com
has not been compensated for its efforts in presenting the Rochester Medical profile on its website and distributing it to its
database of subscribers. SmallCapReview.com
may decide to purchase or sell shares on a voluntary basis in the open
market before, during or after the profiling period of this report.
Information presented on our web site and within our reports contain
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as “expects’”, “will,” “anticipates,”
“estimates, “believes,” or that by statements indicating certain
actions “may,” “could,” or “might” occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
web site.
|